Lower cost strategies for triage of human papillomavirus DNA-positive women

International Journal of Cancer

Volumn 134, Issue 12, 2014, Pages 2891-2901

  Qiao, You Lin ^a   Jeronimo, Jose ^b   Zhao, Fang Hui ^a   Schweizer, Johannes ^c   Chen, Wen ^a   Valdez, Melissa ^b   Lu, Peter ^c   Zhang, Xun ^a   Kang, Le Ni ^a   Bansil, Pooja ^b   Paul, Proma ^b   Mahoney, Charles ^c   Berard Bergery, Marthe ^c   Bai, Ping ^a   Peck, Roger ^b   Li, Jing ^a   Chen, Feng ^a   Stoler, Mark H ^d   Castle, Philip E ^e  

^a CANCER HOSPITAL   (China)

^b PATH   (United States)

^c Arbor Vita Corporation   (United States)

^d UNIVERSITY OF VIRGINIA   (United States)

^e Global Cancer Initiative   (United States)

Author keywords

careHPV; cervical cancer; developing countries; E6; HPV; triage

Indexed keywords

PROTEIN E6;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER SCREENING; CHINA; COLPOSCOPY; CONTROLLED STUDY; COST CONTROL; DIAGNOSTIC TEST ACCURACY STUDY; DNA DETERMINATION; EMERGENCY HEALTH SERVICE; FEMALE; HEALTH CARE COST; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN TISSUE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; PAPILLOMAVIRUS INFECTION; PRECANCER; PREDICTIVE VALUE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX BIOPSY; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU;

CAREHPV; CERVICAL CANCER; DEVELOPING COUNTRIES; E6; HPV; TRIAGE;

ADULT; AGED; CERVICAL INTRAEPITHELIAL NEOPLASIA; CHINA; COLPOSCOPY; DNA, VIRAL; DNA-BINDING PROTEINS; EARLY DETECTION OF CANCER; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMAN PAPILLOMAVIRUS DNA TESTS; HUMANS; MASS SCREENING; MIDDLE AGED; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS INFECTIONS; PRECANCEROUS CONDITIONS; REPRESSOR PROTEINS; SENSITIVITY AND SPECIFICITY; TRIAGE; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 84898004845     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28616     Document Type: Article

References (38)

1. International Agency for Research on Cancer. IARC handbooks of cancer prevention: cervix cancer screening. Lyon, France: IARC Press, 2005.
2. Ferlay J, Shin HR, Bray F, et al. Globocan 2008 V1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. International Agency for Research on Cancer 2010 [cited April 2, 2013]; Available from: URL: http://globocan.iarc.fr/.
3. Kitchener HC, Castle PE, Cox JT,. Chapter 7: achievements and limitations of cervical cytology screening. Vaccine 2006; 24: S3-63-70.
4. Cuzick J, Clavel C, Petry KU, et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 2006; 119: 1095-101.
5. Mayrand MH, Duarte-Franco E, Rodrigues I, et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med 2007; 357: 1579-88.
6. Naucler P, Ryd W, Tornberg S, et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 2007; 357: 1589-97.
7. Rijkaart DC, Berkhof J, Rozendaal L, et al. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol 2012; 13: 78-88.
8. Ronco G, Giorgi-Rossi P, Carozzi F, et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol 2010; 11: 249-57.
9. Castle PE, Stoler MH, Wright TC, Jr,., et al. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. Lancet Oncol 2011; 12: 880-90.
10. Stoler MH, Schiffman M,. Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study. JAMA 2001; 285: 1500-5.
11. Castle PE, Wheeler CM, Solomon D, et al. Interlaboratory reliability of Hybrid Capture 2. Am J Clin Pathol 2004; 122: 238-45.
12. Carozzi FM, Del MA, Confortini M, et al. Reproducibility of HPV DNA testing by Hybrid Capture 2 in a screening setting. Am J Clin Pathol 2005; 124: 716-21.
13. Dillner J, Rebolj M, Birembaut P, et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ 2008; 337: a1754.
14. Castle PE, Glass AG, Rush BB, et al. Clinical human papillomavirus detection forecasts cervical cancer risk in women over 18 years of follow-up. J Clin Oncol 2012; 30: 3044-50.
15. Kjaer SK, Frederiksen K, Munk C, et al. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. J Natl Cancer Inst 2010; 102: 1478-88.
16. Qiao YL, Sellors JW, Eder PS, et al. A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China. Lancet Oncol 2008; 9: 929-36.
17. Adesina A, Chumba D, Nelson AM, et al. Improvement of pathology in sub-Saharan Africa. Lancet Oncol 2013; 14: e152-e157.
18. Zhao FH, Lewkowitz AK, Hu SY, et al. Prevalence of human papillomavirus and cervical intraepithelial neoplasia in China: a pooled analysis of 17 population-based studies. Int J Cancer 2012; 131: 2929-38.
19. Shi JF, Canfell K, Lew JB, et al. The burden of cervical cancer in China: synthesis of the evidence. Int J Cancer 2012; 130: 641-52.
20. Koshiol J, Lindsay L, Pimenta JM, et al. Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis. Am J Epidemiol 2008; 168: 123-37.
21. Castle PE, Rodriguez AC, Burk RD, et al. Short term persistence of human papillomavirus and risk of cervical precancer and cancer: population based cohort study. BMJ 2009; 339: b2569.
22. Pretorius RG, Zhang WH, Belinson JL, et al. Colposcopically directed biopsy, random cervical biopsy, and endocervical curettage in the diagnosis of cervical intraepithelial neoplasia II or worse. Am J Obstet Gynecol 2004; 191: 430-4.
23. Gage JC, Ajenifuja KO, Wentzensen N, et al. Effectiveness of a simple rapid human papillomavirus DNA test in rural Nigeria. Int J Cancer 2012; 131: 2903-9.
24. Schweizer J, Lu PS, Mahoney CW, et al. Feasibility study of a human papillomavirus E6 oncoprotein test for diagnosis of cervical precancer and cancer. J Clin Microbiol 2010; 48: 4646-8.
25. Moy LM, Zhao FH, Li LY, et al. Human papillomavirus testing and cervical cytology in primary screening for cervical cancer among women in rural China: comparison of sensitivity, specificity, and frequency of referral. Int J Cancer 2010; 127: 646-56.
26. Women's health in rural China. Lancet 2009; 374: 358.
27. Zhao FH, Chen JF, Gao XH, et al. [Effectiveness and health economic analysis of strategies on cervical cancer screening and early diagnosis and treatment]. Zhonghua Zhong Liu Za Zhi 2012; 34: 632-6.
28. Schiffman M, Castle PE, Jeronimo J, et al. Human papillomavirus and cervical cancer. Lancet 2007; 370: 890-907.
29. Zhao FH, Lin MJ, Chen F, et al. Performance of high-risk human papillomavirus DNA testing as a primary screen for cervical cancer: a pooled analysis of individual patient data from 17 population-based studies from China. Lancet Oncol 2010; 11: 1160-71.
30. de Sanjose S, Quint WGV, Alemany L, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010; 11: 1048-56.
31. Smith JS, Lindsay L, Hoots B, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: A meta-analysis update. Int J Cancer 2007; 121: 621-32.
32. Castle PE, Solomon D, Schiffman M, et al. Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities. J Natl Cancer Inst 2005; 97: 1066-71.
33. Saslow D, Solomon D, Lawson HW, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin 2012; 62: 147-72.
34. Sauvaget C, Fayette JM, Muwonge R, et al. Accuracy of visual inspection with acetic acid for cervical cancer screening. Int J Gynaecol Obstet 2011; 113: 14-24.
35. Sritipsukho P, Thaweekul Y,. Accuracy of visual inspection with acetic acid (VIA) for cervical cancer screening: a systematic review. J Med Assoc Thai 2010; 93: S254-S261.
36. Pretorius RG, Kim RJ, Belinson JL, et al. Inflation of sensitivity of cervical cancer screening tests secondary to correlated error in colposcopy. J Low Genit Tract Dis 2006; 10: 5-9.
37. Trimble CL, Piantadosi S, Gravitt P, et al. Spontaneous regression of high-grade cervical dysplasia: effects of human papillomavirus type and HLA phenotype. Clin Cancer Res 2005; 11: 4717-23.
38. Castle PE, Schiffman M, Wheeler CM, et al. Evidence for frequent regression of cervical intraepithelial neoplasia-grade 2. Obstet Gynecol 2009; 113: 18-25.